These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 34937484)

  • 1. Nobel Prize for immune checkpoint inhibitors, understanding the immunological switching between immunosuppression and autoimmunity.
    Motofei IG
    Expert Opin Drug Saf; 2022 May; 21(5):599-612. PubMed ID: 34937484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Malignant Melanoma: Autoimmunity and Supracellular Messaging as New Therapeutic Approaches.
    Motofei IG
    Curr Treat Options Oncol; 2019 May; 20(6):45. PubMed ID: 31056729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rheumatic diseases associated with immune checkpoint inhibitors in cancer immunotherapy.
    Ohnuma K; Hatano R; Dang NH; Morimoto C
    Mod Rheumatol; 2019 Sep; 29(5):721-732. PubMed ID: 30285531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Meta-analysis.
    Jácome AA; Castro ACG; Vasconcelos JPS; Silva MHCR; Lessa MAO; Moraes ED; Andrade AC; Lima FMT; Farias JPF; Gil RA; Prolla G; Garicochea B
    JAMA Netw Open; 2021 Dec; 4(12):e2136128. PubMed ID: 34870682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse events induced by immune checkpoint inhibitors.
    Perdigoto AL; Kluger H; Herold KC
    Curr Opin Immunol; 2021 Apr; 69():29-38. PubMed ID: 33640598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How can we manage the cardiac toxicity of immune checkpoint inhibitors?
    Poto R; Marone G; Pirozzi F; Galdiero MR; Cuomo A; Formisano L; Bianco R; Della Corte CM; Morgillo F; Napolitano S; Troiani T; Tocchetti CG; Mercurio V; Varricchi G
    Expert Opin Drug Saf; 2021 Jun; 20(6):685-694. PubMed ID: 33749484
    [No Abstract]   [Full Text] [Related]  

  • 7. Neurological complications of immune checkpoint inhibitor cancer immunotherapy.
    Zivelonghi C; Zekeridou A
    J Neurol Sci; 2021 May; 424():117424. PubMed ID: 33812689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience.
    Bhatlapenumarthi V; Patwari A; Harb AJ
    J Cancer Res Clin Oncol; 2021 Sep; 147(9):2789-2800. PubMed ID: 33774736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy to treat malignancy in patients with pre-existing autoimmunity.
    Boland P; Pavlick AC; Weber J; Sandigursky S
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
    Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
    Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Managing side effects of immune checkpoint inhibitors in breast cancer.
    Criscitiello C; Corti C; Pravettoni G; Curigliano G
    Crit Rev Oncol Hematol; 2021 Jun; 162():103354. PubMed ID: 34029683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical diagnosis and treatment of immune checkpoint inhibitors-related endocrine dysfunction.
    Duan L; Wang L; Wang H; Si X; Zhang L; Liu X; Li Y; Guo X; Zhou J; Zhu H; Zhang L
    Thorac Cancer; 2020 Apr; 11(4):1099-1104. PubMed ID: 32043816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Summarized Overview.
    Plachouri KM; Vryzaki E; Georgiou S
    Curr Drug Saf; 2019; 14(1):14-20. PubMed ID: 30058498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors.
    Baik AH; Tsai KK; Oh DY; Aras MA
    Clin Sci (Lond); 2021 Mar; 135(5):703-724. PubMed ID: 33686402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and characteristics of neurotoxicity in immune checkpoint inhibitors with focus on neuromuscular events: Experience beyond the clinical trials.
    Bruna J; Argyriou AA; Anastopoulou GG; Alemany M; Nadal E; Kalofonou F; Piulats JM; Simó M; Velasco R; Kalofonos HP
    J Peripher Nerv Syst; 2020 Jun; 25(2):171-177. PubMed ID: 32166812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?
    Franzin R; Netti GS; Spadaccino F; Porta C; Gesualdo L; Stallone G; Castellano G; Ranieri E
    Front Immunol; 2020; 11():574271. PubMed ID: 33162990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Endocrinopathies Associated with Immune Checkpoint Inhibitors].
    Santos MJ
    Acta Med Port; 2022 Mar; 35(3):209-215. PubMed ID: 35077347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of glucocorticoids in the management of immunotherapy-related adverse effects.
    Wang H; Zhou J; Guo X; Li Y; Duan L; Si X; Zhang L
    Thorac Cancer; 2020 Oct; 11(10):3047-3052. PubMed ID: 32893490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opportunistic autoimmunity secondary to cancer immunotherapy (OASI): An emerging challenge.
    Kostine M; Chiche L; Lazaro E; Halfon P; Charpin C; Arniaud D; Retornaz F; Blanco P; Jourde-Chiche N; Richez C; Stavris C
    Rev Med Interne; 2017 Aug; 38(8):513-525. PubMed ID: 28214182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarkers related to immune checkpoint inhibitors therapy.
    Li N; Hou X; Huang S; Tai R; Lei L; Li S; Abuliz A; Wang G; Yang S
    Biomed Pharmacother; 2022 Mar; 147():112470. PubMed ID: 35074251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.